Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Rush Street Interactive Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Rush Street Interactive Inc trades at $18.31 (market cap $2.20B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Rush Street Interactive Inc is more actively traded (4,146,093 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Rush Street Interactive Inc for 13 Days on average.
| DYN | RSI | |
|---|---|---|
Market Cap | $2.86B | $2.20B |
Volume | 3,341,579 | 4,146,093 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $34.52 |
52-Week Low | $14.60 | $15.89 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $2.18B | $1.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
RSI trades at $19.07, up 1.92% with bearish technical signals but strong analyst support. The company shows revenue growth to $1.13B in 2025 with improving cash flow, though net margins remain thin at 2.33%. Recent Q2 2026 earnings beat expectations at $0.15 EPS, while institutional interest grows with BlackRock's $448M investment in August 2026.
Outlook remains positive with 77% analyst buy ratings and $33.75 price target offering 77% upside. Key risks include competitive pressures in online gaming and margin compression. The stock presents growth potential but requires monitoring of profitability trends and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
